Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01774968 · ClinicalTrials.gov registry record · Phase 4
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 325
- Enrollment target
NCT01774968: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT01774968 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 325 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01774968, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 325 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.
Primary Outcome
Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with investigator, baseline total daily dose (TDD; ≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.
Interventions
- DRUG Human Regular U-500 Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-05 |
| Phase | Phase 4 |
What the finished NCT01774968 record still lists
NCT01774968 is an interventional study that assigns participants to a tested intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 1 intervention - of which Human Regular U-500 Insulin is the first listed.
NCT01774968 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01774968 about?
NCT01774968 is a clinical study titled "Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes". The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.
What is the current status of trial NCT01774968?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 325 participants. The study started on 2013-02. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01774968?
The interventions under investigation include: Human Regular U-500 Insulin (DRUG).
Who is sponsoring clinical trial NCT01774968?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01774968's enrollment target sits among peer trials
325 254th of 2000 higher than 1,747 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia